ZBH
Research Snapshot
Static fundamentals, valuation context, and investor signals for ZIMMER BIOMET HOLDINGS, INC. (ZBH).
HEALTHCARE
MEDICAL DEVICES
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
5.6%
ROIC, 17.9% FCF margin
Growth
6.1%
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 2.0x current ratio
Superinvestors
7
Top: Hillman Value Fund (3.5%)
Strengths to research
- Free cash flow margin is healthy at 17.9%.
- Debt/equity looks manageable at 0.0x.
- 7 tracked superinvestors report a position.
- 10 annual periods are available for trend analysis.
Watchouts
- Valuation multiples are limited or unavailable.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for ZBH.
Grade C
56
/ 100
Financial Charts
No financial data available for ZBH (annual).
7 superinvestors own ZBH
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Dodge & Cox Dodge & Cox | 23,542,700 | $2.1B | 1.17% | 0.0% |
| Bill Nygren Oakmark Select Fund | 12,959,939 | $1.2B | 1.56% | 0.0% |
| Harry Burn Sound Shore | 1,052,202 | $95M | 3.19% | 0.0% |
| Robert Olstein Olstein Capital Management | 87,000 | $8M | 1.72% | 0.0% |
| Hillman Value Fund Hillman Value Fund | 55,700 | $5M | 3.50% | 0.0% |
| Mairs & Power Growth Fund Mairs & Power Growth Fund | 8,050 | $728,000 | 0.01% | 0.0% |
| John Rogers Ariel Appreciation Fund | 3,014 | $273,000 | 0.00% | 0.0% |